Santarus' Uceris Beats Asacol, Placebo in Ulcerative Colitis
By Catherine Shaffer
Friday, September 28, 2012
Results from the CORE I trial of Uceris (budesonide) in ulcerative colitis appeared in Gastroenterology, detailing a statistically significant benefit over placebo for inducing remission of the disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.